Mueller R J, Green D, Phair J P
Department of Medicine, Rehabilitation Institute of Chicago, Ill.
South Med J. 1987 Nov;80(11):1360-2. doi: 10.1097/00007611-198711000-00007.
Cefoperazone, a beta-lactam antibiotic with a methylthiotetrazole side chain, has been reported infrequently to cause hypoprothrombinemia and hemorrhage. We retrospectively analyzed the records of 80 patients who had been given this drug for more than 72 hours. Nine patients received vitamin K1 (phytonadione) prophylaxis and had no evidence of hemorrhage. Of the remaining 71 patients, 32 had prothrombin times measured; 14 of them had hypoprothrombinemia. Prothrombin times ranged from 14.8 to 97.3 seconds at a mean of 6.2 days after initiation of therapy. Seven of the 14 patients had clinically significant hemorrhage and five required transfusions. Two patients with clinically evident hemorrhage died during or immediately after cefoperazone therapy. Prothrombin times rapidly returned to normal in all patients treated with phytonadione. We believe hypoprothrombinemia is a more common complication of cefoperazone therapy than is generally acknowledged, and is preventable. Unless clinically contraindicated, we recommend that all patients treated with cefoperazone receive phytonadione prophylaxis.
头孢哌酮是一种带有甲硫四氮唑侧链的β-内酰胺类抗生素,曾有报道称其导致低凝血酶原血症和出血的情况较为罕见。我们回顾性分析了80例接受该药治疗超过72小时患者的记录。9例患者接受了维生素K1(植物甲萘醌)预防治疗,未出现出血迹象。其余71例患者中,32例检测了凝血酶原时间;其中14例出现低凝血酶原血症。在开始治疗后平均6.2天时,凝血酶原时间范围为14.8至97.3秒。14例患者中有7例出现具有临床意义的出血,5例需要输血。2例有明显临床出血的患者在头孢哌酮治疗期间或治疗后立即死亡。接受植物甲萘醌治疗的所有患者凝血酶原时间迅速恢复正常。我们认为,低凝血酶原血症是头孢哌酮治疗比普遍认识到的更常见的并发症,且是可预防的。除非有临床禁忌,我们建议所有接受头孢哌酮治疗的患者接受植物甲萘醌预防治疗。